Pharmaceuticals

A new FDA petition aims to slash drug development costs for copies of even the most complex medicines. Is this the key to global access or a threat to innovation?

A landmark $1.5B+ deal for a Chinese drug marks a major global shift. Haisco's innovative partnership with a US venture is reshaping biotech collaboration.

The American Botanical Council is making a high-stakes play to rebrand coca. Can a strategic campaign of science and media finally sever the link to cocaine?

PTC Therapeutics' Sephience isn't just another drug; it's a potential life-changer for PKU patients, promising to ease the burden of a lifelong restrictive diet.

Takeda's ORZEYFUL, a first-in-class orexin agonist, wins approval in Japan, offering the first treatment for the root cause of Narcolepsy Type 1.

With a new patent, a bold asset pivot, and a top-tier banking partner, PharmAla Biotech is signaling a new phase of commercial maturity in psychedelic medicine.

With federal funds backing its Phase 3 trial for a first-in-class cannabis withdrawal drug, PleoPharma offers a new model for biotech investment.

A 645% surge in contracts is just the headline. The real story is how NetraMark's 'explainable' AI is building trust and changing how we develop new cures.

As AI becomes mission-critical in life sciences, a new mandate emerges: prove it's governed. A look at the shift from adoption to inspection-ready AI.

A new campaign in Newfoundland challenges federal rules, asking why quitting aids are harder to buy than cigarettes, and exposing a booming black market.

A new campaign pressures NB's government to fight federal rules limiting nicotine pouches to pharmacies, igniting a debate on rural access and harm reduction.

Telix's impressive H1 results show more than just profit; they reveal a calculated strategy to build a global radiopharmaceutical powerhouse.

A groundbreaking clinical trial is testing whether a common bone-strengthening drug can 'unmask' and eliminate the hidden HIV reservoir, a critical barrier to a cure.

A novel therapy that disarms rather than kills a deadly superbug offers a glimpse of a post-antibiotic future for patients with a debilitating lung disease.

An acquisition signals more than growth; it’s a strategic redesign of the clinical trial landscape, challenging giants and empowering innovation.

Unauthorized antibiotics and ED drugs sold from a Montreal store reveal a dangerous black market that bypasses health regulations and puts consumers at risk.

A biometrics CRO appoints a physician-AI strategist, signaling a pivotal shift from tech hype to the deep, regulated integration of AI in drug development.

A top exec's move from a device giant to a drug startup signals a major shift. Charles Anderson analyzes why hardware's limits in fighting infection are now biotech's biggest opportunity.

Coultreon Biopharma's strategic hire of Dr. Prista Charuworn signals a major push to advance its novel SIK3 inhibitor in the crowded autoimmune market.

The dermatology giant posts strong revenue but dips in profit, channeling funds into high-impact acquisitions and R&D for underserved skin conditions.